The EU–US trade truce leaves generics untouched but puts branded drugs—the core of Ireland’s export engine—at risk, with multinationals ready to shift production and tweak transfer pricing to protect profits.
The EU–US trade framework announced on 21 August was pitched as a breakthrough in calming transatlantic tensions. Europe will sweep away tariffs on American industrial goods and open wider access for US food and seafood. Washington promises to cap tariffs on most EU exports at 15 per cent, while exempting aircraft, natural resources and generic medicines. Both sides will now negotiate rules of origin to ensure only goods genuinely made in Europe or the US benefit.
For Ireland, the implications are unusually sharp. Goods exports reached a record €223.8bn in 2024, with €72.6bn bound for the US. Pharmaceuticals alone made up €99.9bn, almost half the total. Unlike most EU countries, Ireland is not a generics economy. Its export machine runs on high-margin branded and biologic drugs — oncology blockbusters from Pfizer, immunology therapies from AbbVie, advanced biologics from Johnson & Johnson, Amgen and Merck. For these products the framework is silent. Unless they are later added to the US “MFN-only” list, they could face duties of up to 15 per cent.
A 15 per cent tariff may not sound fatal for products with margins above 70 per cent, but the effect would be immediate. Prices for medicines in the US are set by Medicare and insurers, not by accountants in Dublin. Companies cannot simply pass the costs on. A 15 per cent duty on a €10bn export line means €1.5bn erased from profit. The obvious hedge is to move the last steps of production — sterile filling, final packaging and labelling — into US plants. That makes the product American-made, avoiding tariffs and qualifying for federal procurement programmes that favour domestic output. Leave those steps in Ireland and every shipment risks a new tax at the border.
This sets up a subtle but important shift. Multinationals could keep producing active ingredients and bulk biologics in Cork or Sligo, but the finished box marked “Made in the USA” would leave from Indiana or New Jersey. Official Irish exports would shrink even as the underlying activity remained substantial. For a country already struggling with the distortions of multinational accounting, that distinction matters. GDP figures would fall, current-account balances would weaken, and political turbulence would follow. Yet corporate tax receipts might hold steady, because the profits would still be engineered to flow through Irish subsidiaries.
Transfer pricing is the pivot. US pharma groups have long located their intellectual property in Irish entities, which book licensing income, claim capital allowances and pay low effective rates on global profits. Finished exports provided the tangible activity to justify those flows. If tariffs push final production into the US, companies will not abandon Ireland; they will redesign it. One option is for Irish subsidiaries to remain the patent owners while US plants act as contract manufacturers. Royalties flow back to Dublin, keeping profits intact even if customs data show fewer exports. Another option is to ship active ingredients from Ireland at carefully calibrated transfer prices, with final packaging in America. Either way, Ireland risks becoming less a base of production than a profit-booking hub.
That in turn raises questions about substance. Under the OECD’s DEMPE standard, entities booking intangible-related income must perform the functions and bear the risks of developing and exploiting those assets. For now Ireland can point to thousands of pharma jobs, significant manufacturing operations and regulatory oversight functions that anchor those profits. But if more of the “exploitation” of intellectual property shifts to the US through tariff-driven supply chains, Ireland risks looking less like a genuine production base and more like an accounting centre. At that point, the gap between profits booked in Dublin and real activity on the ground could draw scrutiny not only from Washington but from other tax authorities.
History suggests multinationals will not hesitate to adapt. When US tax reform in 2017 changed incentives, groups quickly rewired intra-company licences. Tariffs now play the same role. If Washington signals that biologics will be taxed unless finished at home, supply chains and profit allocations will pivot. The fine print of the new rules of origin will decide whether an Irish-made biologic is treated as European and tariff-exposed, or whether a final step in the US is enough to re-label it as domestic.
Ireland’s vulnerability is clear: a third of its exports go to America, and corporation tax — dominated by US multinationals — now provides a third of the state’s entire revenue. The trade truce locks in stability for some industries but leaves Ireland’s core export sector dangling on a legal technicality. Generics are safe, everything else is uncertain. That uncertainty alone is enough to push companies to hedge, shifting final steps to the US and protecting access to government procurement. The outcome will not be a collapse of Irish pharma, but a gradual hollowing out. Plants will remain, but with narrower mandates. Export statistics will weaken while royalty flows keep tax revenues buoyant. Ireland risks looking ever more like an accounting hub rather than a production centre — a profile harder to defend under DEMPE rules.
The deeper lesson is that the global tax game has changed. With minimum effective tax rates converging around 15 per cent, the room for arbitrage has narrowed. Industrial policy is now enforced through tariffs, rules of origin and subsidies, not mismatched tax codes. What once looked like bugs in the system are now deliberate features of strategy. For Ireland, the message is stark: its success as a manufacturing base for branded pharmaceuticals depends less on low tax rates than on the trade politics of Washington. If Dublin wants to remain more than a paper hub, it must press hard for biologics to be placed on the zero-tariff list. Otherwise the clean finish in Indiana will become the new default, and Ireland’s pharma miracle will start to look increasingly hollow.
Leave a Reply